Chemoprevention: General perspective

Critical Reviews in Oncology/Hematology

Volumn 33, Issue 3, 2000, Pages 157-167

  Shureiqi, Imad ^a,d   Reddy, Pavan ^a   Brenner, Dean E ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BIOLOGICAL MARKER; CAROTENE; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; RETINOID; SELENIUM; TAMOXIFEN;

ANIMAL MODEL; BREAST CANCER; CANCER; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; SCREENING; TOXICITY TESTING;

EID: 0034101849     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00072-4     Document Type: Article

References (113)

1. Landis S., Murray T., Bolden S., Wingo P. Cancer Statistics, CA. 49:1999;8-31.
2. Hong W., Sporn M. Recent advances in chemoprevention of cancer. Science. 278(5340):1997;1073-1077.
3. Osborne M., Boyle P., Lipkin M. Cancer prevention. Lancet. 349(Suppl II):1997;27-30.
4. Sporn M. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36:1976;2699-2702.
5. Wattenberg L. Chemoprevention of cancer. Cancer Res. 45:1985;1-8.
6. Greenwald P., Kelloff G. The role of chemoprevention in cancer control. IARC Sci. Publ. (Lyon). 139:1996;13-22.
7. Boone C., Kelloff G., Steele V. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res. 52(7):1992;1651-1659.
8. Lippman S., Benner S., Hong W. Cancer chemoprevention. J. Clin. Oncol. 12:1994;851-873.
9. Gescher A., Pastorino U., Plummer S., Manson M. Suppression of tumour development by substances derived from the diet-mechanisms and clinical implications. Br. J. Clin. Pharmacol. 45:1998;1-12.
10. Meyskens F. Principles of human chemoprevention. Hematol. Oncol. Clin. North Am. 12(5):1998;1-7.
11. Lochter A., Sternlicht M., Werb Z., Bissell M. The significance of matrix metalloproteinases during early stages of tumor progression. Ann. N.Y. Acad. Sci. 857:1998;180-193.
12. Reed J. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11(1):1999;68-75.
13. Pearson P., Luijt R. The genetic analysis of cancer. J. Intern. Med. 243:1998;413-417.
14. Loeb L. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res. 72:1998;25-56.
15. Vogelstein B., Fearon E., Hamilton S. et al. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 319:1988;525-532.
16. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
17. O'Shaughnessy J. Chemoprevention of breast cancer. J. Am. Med. Assoc. 275(17):1996;1349-1353.
18. Sekido Y., Fong K.M., Minna J.D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta. 1378(1):1998;F21-59.
19. Kelloff G., Boone C., Steele V. et al. Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. Suppl. 20:1994;1-24.
20. Lippman S., Hittelman W., Lotan R. et al. Recent advances in cancer chemoprevention. Cancer Cell. 3:1991;59-65.
21. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
22. Kawamori T., Rao C., Seibert K., Reddy B. Chemopreventive effect of celecoxib, a specific cyclooxygenase-2 inhibitor on colon carcinogenesis. Cancer Res. 58:1998;409-412.
23. Gottardis M., Bischoff E., Shirley M., Wagoner M., Lamph W., Heyman R. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56(24):1996;5566-5570.
24. Husten L. Raloxifene reduces breast-cancer risk. Lancet. 353(9146):1999;44.
25. Rao C.V., Rivenson A., Simi B., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally, occuring plant phenolic compound. Cancer Res. 55:1995;259-266.
26. Huang M.-T., Lou Y.-R., Ma W., Newmark H.L., Reuhl K.R., Conney A.H. Inhibitory effects of dietary curcumin in forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54:1994;5841-5847.
27. Rao C., Rivenson A., Simi B., Reddy B. Chemoprevention of colon cancer by dietary curcumin. Ann. N.Y. Acad. Sci. 125:1996;201-204.
28. Kawamori T., Lubet R., Steele V., Kelloff G., Kaskey R., Rao C. et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59:1999;597-601.
29. Subramanian M., Sreejayan-Rao M.N.A., Devasagayam T.P.A., Singh B.B. Diminution of singlet oxygen induced DNA damage by curcumin and related antioxidants. Mutat. Res. 311:1994;249-255.
30. Dinkova-Kostova A., Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of phase 2 detoxification enzymes. Carcinogenesis. 20:1999;911-914.
31. Piper J., Singhal S., Salameh M., Torman R., Awasthi Y., Awasthi S. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. J. Biochem. Cell Biol. 30:1998;445-456.
32. Thaloor D., Singh A., Sidhu G., Prasad P., Kleinman H., Maheshwari R. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 9:1998;309-312.
33. Rao C.V., Simi B., Reddy B.S. Inhibition of dietary curcumin of azoxymethane induced ornithine decarboxylase, tyrosine, protein kinase, arachidonic acid metabolism and aberrantcrypt foci formation in the rat colon. Carcinogenesis. 14:1993;2219-2225.
34. Huang M.-T., Lysz T., Ferraro T., Abidi T.F., Laskin J.D., Conney A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 51:1991;813-819.
35. Steele V., Boone C., Lubet R., Crowell J., Holmes C., Sigman C. et al. Preclinical development paradigms for chemopreventives. Hematol. Oncol. Clin. North Am. 12:1998;943-961.
36. Korytynski E., Kelloff G., Suk W. et al. The development of an anchorage-independence assay using human lung tumor cells to screen potential chemopreventive agents. Anticancer Res. 16:1996;1091-1094.
37. Arnold J., Wilkinson B., Sharma S. et al. Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay. Cancer Res. 55:1995;537-543.
38. Steele V., Sharma S., Mehta R. et al. Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents. Cancer Res. 50:1990;2068-2074.
39. Steele V., Sharma S., Mehta R. et al. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell Biochem. 26:1996;29-53.
40. Mehta R., Steele V., Kelloff G. et al. Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res. 11:1991;587-592.
41. Bird R. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:1987;147-151.
42. Siu I., Pretlow T., Amini S., Pretlow T. Identification of dysplasia in human colonic aberrant crypt foci. Am. J. Pathol. 150:1997;1805-1813.
43. Polyak K., Hamilton S., Vogelstein B., Kinzler K. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am. J. Pathol. 149:1996;381-387.
44. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S. et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. New Engl. J. Med. 339:1998;1277-1284.
45. Jen J., Powell S., Papadopoulous N., Smith K., Hamilton S., Vogelstein B. et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:1994;5523-5526.
46. Pretlow T., Brasitus T., Fulton N., Cheyer C., Kaplan E. K-ras mutations in putative prenoeplastic lesions in human colon. J. Natl. Cancer Inst. 85:1993;2004-2007.
47. Smith A., Stern H., Penner M., Hay K., Mitri A., Bapat B. et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54:1994;5527-5530.
48. Hamilton S. Pathogenesis of polyps (adenomas). Dis. Colon Rectum. 26:1983;413-414.
49. Wargovich M., Chen C., Harris C., Yang E., Velasco M. Inibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer. 60(Feb 8):1995;515-519.
50. Reddy B., Rao C., Seibert K. Evaluation of a cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
51. Reddy B. Colon carcinogenesis models for chemoprevention studies. Hematol. Oncol. Clin. North Am. 12:1998;963-973.
52. Su L., Kinzler K., Vogelstein B., Preisinger A., Moser A., Luongo C. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 250:1992;668-670.
53. Beazer-Barclay Y., Levy D., Moser A. et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 17:1996;1757-1762.
54. Jacoby R., Marshall D., Newton M. et al. Chemoprevention of spontaneous intestinal adenomas in Apc Min mouse model by the non-steroidal antiinflammatory drug piroxicam. Cancer Res. 56:1996;710-716.
55. Mahmoud N., Boolbol S., Dannenberg A., Mestre J., Bilinski R., Martucci C. et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 19:1998;87-91.
56. Chiu C., McEntee M., Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 57:1997;4267-4271.
57. Piazza G., Alberts D., Hixon L., Paranka N., Li H., Finn T. et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57:1997;2909-2915.
58. Boolbol S., Dannenberg A., Chadburn A., Martucci C., Guo X., Ramonetti J. et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
59. Goodman G. The clinical evaluation of chemoprevention agents: defining and contrasting phase I, II, III objectives. Cancer Res. 52:1992;2752-2758.
60. Burstein H., Gelber S., Guadagnoli E., Weeks J. Use of alternative medicine by women with early-stage breast cancer. New Engl. J. Med. 340:1999;1733-1739.
61. Nam R., Fleshner N., Rakovitch E., Klotz L., Trachtenberg J., Choo R. et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J. Urol. 161:1999;1521-1524.
62. Reifel J., Ganz P. Quality of life research: clinical applications. Cancer Treat. Res. 97:1998;1-12.
63. Waterhouse D., Calzone K., Mele C., Brenner D. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 11:1993;1189-1197.
64. Dunbar J., Strunkard A. Adherence to diet and drug regimen. Levy R., Rivkind B., Dennis B. Nutrition, Lipids, and Coronary Artery Disease. 1979;391-423 Raven Press, New York.
65. Becker M. Adherence to prescribed therapies. Med. Care. 23(3):1985;539-554.
66. Urquhart J. Nonadherence: the ultimate absorption barrier. Prescott L., Nimmo W. Novel Drug Delivery and its Therapeutic Application. 1989;127-137 Wiley, Philadelphia.
67. Rudd P. In search of the gold standard for adherence measurement. Arch. Intern. Med. 139:1979;627-628.
68. Skinner C., Strecher V., Hospers H. Physicians' recommendations for mammography: do tailored messages make a difference? Am. J. Publ. Health. 84:1994;43-49.
69. Baron J.A., Beach M., Mandel J.S., van Stolk R.U., Haile R.W., Sandler R.S. et al. Calcium supplements for the prevention of colorectal adenomas, Calcium Polyp Prevention Study Group. New Engl. J. Med. 340(2):1999;101-107.
70. Fisher B., Costantino J., Wickerham D., Redmond C., Kavanah M., Cronin W. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388.
71. Blot W., Li J., Taylor P. et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence and disease specific mortality in the general population. J. Natl. Cancer Inst. 85:1993;1483-1492.
72. Burney K., Krishnan K., Ruffin M., Zhang D., Brenner D. Adherence to single daily dose of aspirin in a chemoprevention trial: an evaluation of self-report and microelectronic monitoring. Arch. Fam. Med. 5:1996;297-300.
73. Fabian C., Kimler B., Elledge R., Grizzle W., Beenken S., Ward J. Models for early chemoprevention trials in breast cancer. Hematol. Oncol. Clin. North Am. 12:1998;993-1017.
74. Dunn B., Kramer B., Ford L. Phase III large-scale chemoprevention trials. Hematol. Oncol. Clin. North Am. 12:1998;1019-1036.
75. Lippman S., Lee J., Sabichi A. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst. 90(20):1998;1514-1518.
76. Ruffin M., Krishnan K., Rock C., Normolle D., Vaerten M., Peters-Golden M. et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J. Natl. Cancer Inst. 89:1997;1152-1160.
77. Baron J. The clinical utility of risk factor data. J. Clin. Epidemiol. 42:1989;1013-1020.
78. Baron J., Tosteson T., Wargovich M., Sandler R., Mandel J., Bond J. et al. Calcium supplementation and rectal mucosal proliferation: a randomized controlled trial. J. Natl. Cancer Inst. 87:1995;1303-1307.
79. Baron J., Wargovich M., Tosteson T., Sandler R., Haile R. Epidemiological use of rectal proliferation measures. Cancer Epidemiol. Biomarkers Prev. 4:1995;57-61.
80. Potter C., Beldock J., Rosenthal G., Osborne M. A clinician-friendly computer program for calculating breast cancer risk using the Gail and Claus models. Ann. N.Y. Acad. Sci. 768:1995;301-307.
81. Vogel V. Assessing women's potential risk of developing breast cancer. Oncology. 10(10):1996;1451-1458.
82. Anonymous. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, J Clin Oncol 1996;14:1730-1736.
83. Anonymous. Screening for colorectal cancer - United States, 1997, Morb Mort Wkly Rep 1999;48[6]:116-21.
84. Kinzler K., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
85. Stamler J., Stamler R., Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks, US population data. Arch. Intern. Med. 153:1993;598-615.
86. Rubenfire M., Coletti A., Mosca L. Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Prog. Cardiovasc. Dis. 41:1998;95-116.
87. Anonymous. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Panel II), J Am Med Assoc 1993;269:3015-3023.
88. Bycott P., Taylor J. An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. Controlled Clin. Trials. 19:1998;555-568.
89. Bycott P., Taylor J. An evaluation of the proportion of the treatment effect explained by a surrogate marker. Controlled Clin. Trials. 18:1999;233-243.
90. Rustin G., Nelstrop A., Bentzen S., Piccart M., Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann. Oncol. 10((Suppl)):1999;21-27.
91. O'Riordan D., Deery A., Dorman A., Epstein O. Increased CA 125 in a patient with tuberculous peritonitis: case report and review of published works. Gut. 36:1995;303-305.
92. Bell R., Petticrew M., Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br. J. Obstet. Gynecol. 105:1998;1136-1147.
93. Rosenthal A., Jacobs I. Ovarian cancer screening. Semin. Oncol. 25:1998;315-325.
94. Partin A., Oesterling J. The clinical usefulness of prostate specific antigen: update. J. Urol. 1994(152):1994;1358-1368.
95. Tchetgen M., Oesterling J. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol. Clin. North Am. 24:1997;283-291.
96. Mettlin C., Littrup P., Kane R., Murphy G., Lee F., Chesley A. et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 74:1994;1615-1620.
97. Lippman S., Lec J., Lotan R. et al. Biomarkers as intermediate endpoints in chemoprevention trials. J. Natl. Cancer Inst. 82:1990;555.
98. Winawer S.J., Zauber A.G., Ho M.N., O'Brien M.J., Gottlieb L.S., Sternberg S.S. et al. Prevention of colorectal cancer by colonoscopic polypectomy. New Engl. J. Med. 329:1993;1777-1781.
99. Spechler S. Barrett's esophagus. Semin. Oncol. 21:1994;431-437.
100. Sober A., Burstein J. Precursors to skin cancer. Cancer. 75((suppl)):1995;645-650.
101. Tucker M., Halpern A., Holly E., Hartge P., Elder D., Sagebiel R. et al. Clinically recognized dysplastic nevi, a central risk factor for cutaneous melanoma. J Am Med Assoc. 277:1997;1439-1444.
102. Gustafsson L., Adami H.-O. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br. J. Cancer. 60:1989;132-137.
103. Cawson R. Premalignant lesions in the mouth. Br. Med. Bull. 31:1975;164-180.
104. Kelloff G., Lieberman R., Brawer M., Crawford E., Labrie F., Miller G. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis. 2(suppl 1):1999;27-33.
105. Kelloff G., Boone C., Crowell J. et al. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem. 25S:1996;1-14.
106. Moon T., Levine N., Cartmel B. et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol. Biomark. Prev. 6(11):1997;949-956.
107. Omenn G., Goodman G., Thornquist M., Balmes J., Cullen M., Glass A.K. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New Engl. J. Med. 334(18):1996;1150-1155.
108. Heinonen O., Albanes D. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. New Engl. J. Med. 330:1994;1029-1035.
109. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Lancet. 352:1998;93-97.
110. Powles T., Eeles R., Ashley S., Easton D., Chang J., Sowsett M. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 351:1998;1451-1467.
111. Gruber S., Petersen G., Kinzler K., Vogelstein B. Cancer, crash sites, and the new genetics of neoplasia. Gastroenterology. 116:1999;210-212.
112. Laken S., Petersen G., Gruber S., Oddoux C., Ostrer H., Giardiello F. et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat. Genet. 17:1997;79-83.
113. Rozen P., Shomrat R., Strul H., Naiman T., Karminsky N., Legum C. et al. Prevalence of the I1307K APC variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology. 116:1999;54-57.